Amit Sachdev - Vertex Pharmaceuticals President

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  President
Mr. Amit K. Sachdev, J.D., is Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO of the Vertex Pharmaceuticals Incorporated. He served as our Executive Vice President, Policy, Access and Value, from October 2014 through December 2016. In 2007, he joined us as a Senior Vice President, and has led our government affairs and public policy activities, as well as our patient advocacy programs. From 2010 through 2013 he established our first international commercial operations in Canada. Prior to joining us, Mr. Sachdev served as Executive Vice President, Health of the Biotechnology Industry Organization and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the United States House of Representatives and practiced law at the Chemical Manufacturers Association, and subsequently at the law firm of Ropes Gray LLP
Age: 50  President Since 2017      
617 341-6100  www.vrtx.com
Sachdev holds a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law.

Amit Sachdev Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

James DillardPerrigo Company Plc
2019
Grainne QuinnPerrigo Company Plc
2016
Alejandro BernalZoetis
2015
Jatin ShahPerrigo Company Plc
2005
Jeffrey NeedhamPerrigo Company Plc
2009
Marc CouckePerrigo Company Plc
N/A
Joseph LaRosaRegeneron Pharmaceuticals
2019
Roxanne LaganoZoetis
2015
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Umang VohraDr Reddys Laboratories Ltd
2013
Sandra BeatyZoetis
2012
Scott JamisonPerrigo Company Plc
2011
Michael AbermanRegeneron Pharmaceuticals
2015
Samiran DasDr Reddys Laboratories Ltd
2016
Clinton LewisZoetis
2018
Thomas FarringtonPerrigo Company Plc
2015
George YancopoulosRegeneron Pharmaceuticals
2016
Douglas BoothePerrigo Company Plc
2013
Alok SonigDr Reddys Laboratories Ltd
2015
J RamachandranDr Reddys Laboratories Ltd
2016
Douglas McCorkleRegeneron Pharmaceuticals
2007

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased one share of
few hours ago
Traded for 211.11
Purchased one share of
few hours ago
Traded for 3.38
Purchased one share of
few hours ago
Traded for 208.57
Also please take a look at World Market Map. Please also try CEO Directory module to screen ceos from public companies around the world.
Search macroaxis.com